110 related articles for article (PubMed ID: 16372535)
1. Enzastaurin and pemetrexed exert synergistic antitumor activity in thyroid cancer cell lines in vitro.
Oberschmidt O; Eismann U; Schulz L; Struck S; Blatter J; Lahn MM; Ma D; Hanauske AR
Int J Clin Pharmacol Ther; 2005 Dec; 43(12):603-4. PubMed ID: 16372535
[No Abstract] [Full Text] [Related]
2. Molecular pathways involved in the synergistic interaction of the PKC beta inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cells.
Tekle C; Giovannetti E; Sigmond J; Graff JR; Smid K; Peters GJ
Br J Cancer; 2008 Sep; 99(5):750-9. PubMed ID: 18728666
[TBL] [Abstract][Full Text] [Related]
3. Pemetrexed, a multitargeted antifolate drug, demonstrates lower efficacy in comparison to methotrexate against osteosarcoma cell lines.
Bodmer N; Walters DK; Fuchs B
Pediatr Blood Cancer; 2008 Apr; 50(4):905-8. PubMed ID: 17534933
[TBL] [Abstract][Full Text] [Related]
4. Clinical potency of methotrexate, aminopterin, talotrexin and pemetrexed in childhood leukemias.
Norris RE; Adamson PC
Cancer Chemother Pharmacol; 2010 May; 65(6):1125-30. PubMed ID: 19784838
[TBL] [Abstract][Full Text] [Related]
5. Schedule-dependent synergism and antagonism between pemetrexed and paclitaxel in human carcinoma cell lines in vitro.
Kano Y; Akutsu M; Tsunoda S; Izumi T; Mori K; Fujii H; Yazawa Y; Mano H; Furukawa Y
Cancer Chemother Pharmacol; 2004 Dec; 54(6):505-13. PubMed ID: 15340759
[TBL] [Abstract][Full Text] [Related]
6. Role of folic acid in modulating the toxicity and efficacy of the multitargeted antifolate, LY231514.
Worzalla JF; Shih C; Schultz RM
Anticancer Res; 1998; 18(5A):3235-9. PubMed ID: 9858888
[TBL] [Abstract][Full Text] [Related]
7. Interaction of pemetrexed disodium (ALIMTA, multitargeted antifolate) and irradiation in vitro.
Bischof M; Weber KJ; Blatter J; Wannenmacher M; Latz D
Int J Radiat Oncol Biol Phys; 2002 Apr; 52(5):1381-8. PubMed ID: 11955753
[TBL] [Abstract][Full Text] [Related]
8. [Folic acid antagonists pemetrexed].
Heinzl S
Med Monatsschr Pharm; 2004 Jul; 27(7):220-2. PubMed ID: 15296355
[No Abstract] [Full Text] [Related]
9. Pemetrexed: mRNA expression of the target genes TS, GARFT and DHFR correlates with the in vitro chemosensitivity of human solid tumors.
Eismann U; Oberschmidt O; Ehnert M; Fleeth J; Lüdtke FE; Struck S; Schulz L; Blatter J; Lahn MM; Ma D; Niyikiza C; Paoletti P; Hanauske AR
Int J Clin Pharmacol Ther; 2005 Dec; 43(12):567-9. PubMed ID: 16372519
[No Abstract] [Full Text] [Related]
10. Enzastaurin, a protein kinase C beta inhibitor, suppresses signaling through the ribosomal S6 kinase and bad pathways and induces apoptosis in human gastric cancer cells.
Lee KW; Kim SG; Kim HP; Kwon E; You J; Choi HJ; Park JH; Kang BC; Im SA; Kim TY; Kim WH; Bang YJ
Cancer Res; 2008 Mar; 68(6):1916-26. PubMed ID: 18339873
[TBL] [Abstract][Full Text] [Related]
11. An overview of folate metabolism: features relevant to the action and toxicities of antifolate anticancer agents.
Calvert H
Semin Oncol; 1999 Apr; 26(2 Suppl 6):3-10. PubMed ID: 10598549
[No Abstract] [Full Text] [Related]
12. Enzastaurin.
Ma S; Rosen ST
Curr Opin Oncol; 2007 Nov; 19(6):590-5. PubMed ID: 17906457
[TBL] [Abstract][Full Text] [Related]
13. Loss of reduced folate carrier function and folate depletion result in enhanced pemetrexed inhibition of purine synthesis.
Zhao R; Zhang S; Hanscom M; Chattopadhyay S; Goldman ID
Clin Cancer Res; 2005 Feb; 11(3):1294-301. PubMed ID: 15709201
[TBL] [Abstract][Full Text] [Related]
14. Pemetrexed, a novel antifolate therapeutic alternative for cancer chemotherapy.
Villela LR; Stanford BL; Shah SR
Pharmacotherapy; 2006 May; 26(5):641-54. PubMed ID: 16637794
[TBL] [Abstract][Full Text] [Related]
15. Recombinant erythropoietin differently affects proliferation of mesothelioma cells but not sensitivity to cisplatin and pemetrexed.
Palumbo C; Battisti S; Carbone D; Albonici L; Alimandi M; Bei R; Modesti A
Cancer Chemother Pharmacol; 2008 Apr; 61(5):893-901. PubMed ID: 17922127
[TBL] [Abstract][Full Text] [Related]
16. Characterization of a folate transporter in HeLa cells with a low pH optimum and high affinity for pemetrexed distinct from the reduced folate carrier.
Wang Y; Zhao R; Goldman ID
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6256-64. PubMed ID: 15448015
[TBL] [Abstract][Full Text] [Related]
17. Sequence-dependent administration of raloxifene and 5-fluorouracil/pemetrexed protects against pemetrexed cytotoxicity in human bone marrow.
Das JR; Fryar-Tita EB; Green S; Southerland WM; Bowen D
Anticancer Res; 2007; 27(2):825-33. PubMed ID: 17465208
[TBL] [Abstract][Full Text] [Related]
18. Preclinical evaluation of pemetrexed in pediatric solid tumors.
Norris RE; Rappaport EF; Adamson PC
Pediatr Blood Cancer; 2011 Dec; 57(7):1233-5. PubMed ID: 21850675
[TBL] [Abstract][Full Text] [Related]
19. Antifolates: the next millennium.
Allegra CJ
Semin Oncol; 1999 Apr; 26(2 Suppl 6):1-2. PubMed ID: 10598548
[No Abstract] [Full Text] [Related]
20. Glutamyl hydrolase: properties and pharmacologic impact.
Galivan J; Ryan T; Rhee M; Yao R; Chave K
Semin Oncol; 1999 Apr; 26(2 Suppl 6):33-7. PubMed ID: 10598552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
